Medicare drug value negotiations what’s forward in 2024

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the …

Weight problems and Alzheimer’s medicine pack one-two punch to carry Eli Lilly

Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer …

Bristol Myers Squibb to purchase Karuna Therapeutics

Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers’ drug pipeline after …

New information on Eli Lilly’s weight-loss drug exhibits its outlook is vivid

The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled …

Moderna, Merck most cancers vaccine reduces danger of pores and skin most cancers return

An exterior view of Moderna’s clinical manufacturing facility.  David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage …

First CRISPR gene-editing remedy authorized in U.S.

The U.S. Food and Drug Administration on Friday approved the country’s first gene-editing treatment, Casgevy, for use in patients with sickle cell disease. The approval comes about a decade after the discovery of CRISPR technology for editing human DNA, representing a significant scientific advancement. Yet reaching the tens of thousands of people who could benefit …

Free ChatGPT might incorrectly reply drug questions, research says

Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions …

Novo Nordisk sues pharmacies over impure Wegovy, Ozempic dupes

A 0.25 mg injection pen of Novo Nordisk’s weight loss drug Wegovy is shown in this photo in Oslo, Norway, on Aug. 31, 2023. Victoria Klesty | Reuters Novo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and “potentially unsafe” drugs claiming to contain semaglutide, the active ingredient …

China says no new pathogens detected amid surge in respiratory diseases

Crowd gathers during China’s Lunar New Year celebrations. Nurphoto | Getty Images Chinese authorities reportedly called for vigilance Friday as a spike in respiratory illness continues to pile pressure on health care facilities in the north of the country, despite assurances that no “unusual or novel pathogens” have been detected. The World Health Organization said …

Free at dwelling Covid checks obtainable beginning Monday

COVID-19 home test kits are pictured in a store window during the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., January 19, 2022. Carlo Allegri | Reuters The Biden administration on Monday said it is offering another round of free at-home Covid tests to U.S. households ahead of …